Equities

Check Cap Ltd

Check Cap Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.19
  • Today's Change-0.010 / -0.45%
  • Shares traded3.56k
  • 1 Year change+57.56%
  • Beta0.1632
Data delayed at least 15 minutes, as of May 06 2024 16:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.62m
  • Incorporated2009
  • Employees85.00
  • Location
    Check Cap Ltd29 Abba Hushi Ave., IsfiyaP.O.Box 1271 3009000IsraelISR
  • Phone+972 48303401
  • Fax+972 48211267
  • Websitehttps://check-cap.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pioneer Green Farms Inc9.29k-403.37k11.94m6.00------1,285.15-0.0172-0.01720.0004-0.0260.01540.3035--1,548.33-66.94------41.44---4,341.98--0.0106-30.89--------35.41------
ELEVAI Labs Inc1.71m-4.30m12.15m18.00--3.17--7.09-0.2482-0.24820.09880.2208------95,143.89--------66.25---251.17--3.41-41.160.00--123.50---138.94------
Viaderma Inc17.80m2.31m12.28m75.000.00060.000042.270.6916.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Energy Finders Inc4.06m-2.92m12.30m46.00------3.03-0.272-0.2721.523.04------88,304.35--------27.45---71.79--0.6706-12.570.564--------------
Imunon Inc0.00-19.51m12.50m33.00--0.9338-----2.17-2.170.001.420.00----0.00-59.23-50.18-80.53-60.27-------5,725.88----0.00---100.00--45.64--26.69--
Monopar Therapeutics Inc0.00-8.40m12.69m10.00--1.94-----0.612-0.6120.000.37490.00----0.00-81.69-54.07-107.13-60.60------------0.00------20.10------
Check Cap Ltd0.00-17.62m12.87m85.00--0.4698-----3.01-3.010.004.680.00----0.00-44.86-58.80-48.21-66.41------------0.00-------11.08--16.04--
Coeptis Therapeutics Holdings Inc0.00-21.27m12.99m5.00--2.95-----0.8922-0.89220.000.12210.00----0.00-266.05-36.90-392.90-37.81------------0.2068------43.40------
NanoViricides Inc0.00-9.36m13.31m7.00--1.15-----0.8004-0.80040.000.98280.00----0.00-55.47-43.54-57.90-46.29------------0.00-------5.94---8.90--
Actavia Life Sciences Inc0.00-4.44m13.35m1.00---------0.0074-0.00740.00-0.00270.00----0.00-10,235.89-158.17---------------21.20---------547.04------
Lotus Pharmaceuticals Inc70.79m1.72m13.47m233.000.09040.00143.490.19030.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Kiora Pharmaceuticals Inc0.00-13.04m13.48m12.00--0.6474-----2.98-2.980.000.79290.00----0.00-77.27-70.52-91.06-81.86-------2,040.61----0.00------3.97------
Dominari Holdings Inc2.04m-22.88m13.65m26.00--0.2579--6.69-4.44-4.440.38998.920.0305--0.382978,423.08-34.20-26.82-35.10-27.45-----1,122.22-3,353.52----0.00----135.7512.72--63.99--
Pieris Pharmaceuticals Inc42.81m-24.54m13.70m46.00--0.5121--0.3201-22.94-22.9438.0321.640.6382--13.42930,652.20-36.58-28.41-57.30-39.69-----57.33-94.61----0.00--65.288.0326.25---36.82--
Data as of May 06 2024. Currency figures normalised to Check Cap Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.06%Per cent of shares held by top holders
HolderShares% Held
Nantahala Capital Management LLCas of 31 Dec 202333.40k0.57%
Dimensional Fund Advisors LPas of 31 Dec 202314.90k0.26%
UBS Securities LLCas of 31 Dec 20235.19k0.09%
Morgan Stanley & Co. LLCas of 31 Dec 20235.14k0.09%
American Portfolios Advisors, Inc.as of 31 Dec 20231.62k0.03%
IFP Advisors, Inc.as of 31 Dec 2023500.000.01%
Securities America Advisors, Inc.as of 31 Dec 2023500.000.01%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Dec 2023300.000.01%
Harbour Investments, Inc.as of 31 Dec 2023275.000.01%
Concourse Financial Group Securities, Inc.as of 31 Mar 2024213.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.